Author/Authors :
Torabi, Raheleh Department of Medical Genetics - National Institute for Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran , Zarei, Saeed Monoclonal Antibody Research Center - Avicenna Research Institute, ACECR, Tehran, Iran , Zeraati, Hojjat Department of Epidemiology and Biostatistics - School of Public Health - Tehran University of Medical Sciences, Tehran, Iran , Zarnani, Amir Hassan Nanobiotechnology Research Center - Avicenna Research Institute, ACECR, Tehran, Iran , Akhondi, Mohammad Mehdi Reproductive Biotechnology Research Center - Avicenna Research Institute, ACECR, Tehran, Iran , Hadavi, Reza Monoclonal Antibody Research Center - Avicenna Research Institute, ACECR, Tehran, Iran , Savadi Shiraz, Elham Reproductive Biotechnology Research Center - Avicenna Research Institute, ACECR, Tehran, Iran , Jeddi-Tehrani, Mahmood Monoclonal Antibody Research Center - Avicenna Research Institute, ACECR, Tehran, Iran
Abstract :
Background: Recurrent pregnancy loss is (RPL) a heterogeneous condition. While
the role of acquired thrombophilia has been accepted as an etiology for RPL, the
contribution of specific inherited thrombophilic gene polymorphisms to the disorder
has been remained controversial.
Methods: One hundred women with a history of two or more consecutive abortions
and 100 women with at least two live births and no miscarriages were included in the
study and evaluated for the presence of 11 thrombophilic gene polymorphisms (Factor V LEIDEN, Factor V 4070 A/G, Factor V 5279 A/G, Factor XIII 103 G/T, Factor XIII 614 A/T, Factor XIII 1694 C/T, PAI-1 -675 4G/5G, ITGB3 1565 T/C, β-Fibrinogen -455G/A, MTHFR 677 C/T, MTHFR 1298 A/C) using PCR-RFLP technique.
The data were statistically analyzed using Mann-Whitney test and logistic regression
model.
Results: There was no relation between factor XIII 103G/T gene polymorphism with
increased risk of RPL. However, the other 10 gene polymorphisms were found to be
associated with increased/decreased risk of RPL. Multiple logistic regression model
for analyzing the simultaneous effects of these polymorphisms on the risk of RPL
showed that six of these 11 polymorphisms (Factor V 1691G/A, Factor V 5279A/G, Factor XIII 614A/T, β-Fibrinogen -455G/A, ITGB3 1565T/C, and MTHFR 1298A/C) were associated with RPL.
Conclusion: It is possible to calculate the risk of abortion in a patient with RPL by determining only six of the 10 polymorphisms that are individually associated with RPL.
